Advertisement
Advertisement
September 21, 2021
LSO Medical’s Lumeseal Next-Generation EVLT Platform Receives CE Mark Approval
September 21, 2021—LSO Medical SAS, a France-based developer of vascular laser therapies, announced CE-Mark approval for the Lumeseal laser platform, the company’s newest generation SnakeBack-assisted endovenous laser treatment (EVLT) system.
According to LSO Medical, Lumeseal, which is the successor of the company’s Endotherme 1470 platform, is designed to enhance ease of use and to provide greater precision and control throughout the procedure.
The third-generation EVLT system combines a 1,470-nm laser with the company’s Ringlight radial fibers range design. In addition, Lumeseal incorporates LSO Medical’s SnakeBack technology, which is a tensionless, assisted-pullback system that enables physicians to plan, apply, and monitor energy profiles delivered into the vein. The integration of these technologies allows total supervision of the vein occlusion while maintaining the usual touch feel feedback during the procedure.
Because of the international shortage affecting semiconductor technology, a limited commercial release of the Lumeseal is planned for Fall 2021 with a full launch anticipated in early 2022, advised LSO Medical.
Advertisement
Advertisement
